JP7659499B2 - 線維症を治療又は予防するための組成物及び方法 - Google Patents

線維症を治療又は予防するための組成物及び方法 Download PDF

Info

Publication number
JP7659499B2
JP7659499B2 JP2021547960A JP2021547960A JP7659499B2 JP 7659499 B2 JP7659499 B2 JP 7659499B2 JP 2021547960 A JP2021547960 A JP 2021547960A JP 2021547960 A JP2021547960 A JP 2021547960A JP 7659499 B2 JP7659499 B2 JP 7659499B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
polypeptide
fibrosis
composition according
liver
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021547960A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022509445A (ja
JP2022509445A5 (https=
Inventor
ハン，チュンソン
ウ，ドン－フン
ジン，シオン
リ，ジェフン
アン，グン，ホ
ユ，タク，ジン
チュン，ジンウ
Original Assignee
ネクセル カンパニー，リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020180128033A external-priority patent/KR102129178B1/ko
Priority claimed from KR1020180128204A external-priority patent/KR102129179B1/ko
Priority claimed from KR1020180128625A external-priority patent/KR102161892B1/ko
Application filed by ネクセル カンパニー，リミテッド filed Critical ネクセル カンパニー，リミテッド
Publication of JP2022509445A publication Critical patent/JP2022509445A/ja
Publication of JP2022509445A5 publication Critical patent/JP2022509445A5/ja
Priority to JP2024092192A priority Critical patent/JP2024133483A/ja
Application granted granted Critical
Publication of JP7659499B2 publication Critical patent/JP7659499B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
JP2021547960A 2018-10-25 2019-10-24 線維症を治療又は予防するための組成物及び方法 Active JP7659499B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024092192A JP2024133483A (ja) 2018-10-25 2024-06-06 線維症を治療又は予防するための組成物及び方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
KR10-2018-0128204 2018-10-25
KR10-2018-0128033 2018-10-25
KR1020180128033A KR102129178B1 (ko) 2018-10-25 2018-10-25 심근경색 예방 또는 치료용 재조합 단백질을 포함하는 심근경색 예방 또는 치료용 조성물
KR1020180128204A KR102129179B1 (ko) 2018-10-25 2018-10-25 알츠하이머병 예방 또는 치료용 재조합 단백질을 포함하는 알츠하이머병 예방 또는 치료용 조성물
KR1020180128625A KR102161892B1 (ko) 2018-10-26 2018-10-26 특발성 폐섬유증 예방 또는 치료용 재조합 단백질을 포함하는 특발성 폐섬유증 예방 또는 치료용 조성물
KR10-2018-0128625 2018-10-26
PCT/IB2019/001136 WO2020084344A2 (en) 2018-10-25 2019-10-24 Compositions and methods for treating or preventing fibrosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024092192A Division JP2024133483A (ja) 2018-10-25 2024-06-06 線維症を治療又は予防するための組成物及び方法

Publications (3)

Publication Number Publication Date
JP2022509445A JP2022509445A (ja) 2022-01-20
JP2022509445A5 JP2022509445A5 (https=) 2022-10-27
JP7659499B2 true JP7659499B2 (ja) 2025-04-09

Family

ID=70331794

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021547960A Active JP7659499B2 (ja) 2018-10-25 2019-10-24 線維症を治療又は予防するための組成物及び方法
JP2024092192A Withdrawn JP2024133483A (ja) 2018-10-25 2024-06-06 線維症を治療又は予防するための組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024092192A Withdrawn JP2024133483A (ja) 2018-10-25 2024-06-06 線維症を治療又は予防するための組成物及び方法

Country Status (5)

Country Link
US (2) US12139518B2 (https=)
EP (1) EP3870210A4 (https=)
JP (2) JP7659499B2 (https=)
CN (1) CN113301914B (https=)
WO (1) WO2020084344A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7659499B2 (ja) * 2018-10-25 2025-04-09 ネクセル カンパニー，リミテッド 線維症を治療又は予防するための組成物及び方法
MX2022002638A (es) 2019-09-06 2022-03-25 Novartis Ag Proteinas de fusion terapeuticas.
KR102801198B1 (ko) * 2021-06-28 2025-04-30 (주) 넥셀 특발성 폐섬유증 예방 또는 치료용 폴리펩타이드 및 이를 포함하는 약학 조성물
KR102758046B1 (ko) * 2021-11-05 2025-01-23 (주) 넥셀 궤양성 대장염 예방 또는 치료용 재조합 단백질 및 이를 포함하는 궤양성 대장염 예방 또는 치료용 조성물
CN118633748A (zh) * 2024-05-29 2024-09-13 哈尔滨工业大学 一种包含乳源mfg-e8的产品及其在改善衰老、学习和/或记忆障碍中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002530348A (ja) 1998-11-24 2002-09-17 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ラクトアドヘリン又はその変異体を用いる組成物及び方法
WO2015025956A1 (ja) 2013-08-22 2015-02-26 国立大学法人九州大学 心筋障害治療用薬剤組成物、心筋障害予防用薬剤組成物、心不全治療用薬剤組成物、心不全予防用薬剤組成物、心筋障害又は心不全を治療又は予防する方法、ｍｆｇ－ｅ８、ｍｆｇ－ｅ８の使用、及び心筋障害又は心不全を治療又は予防する化合物のスクリーニング方法
JP6585296B2 (ja) 2017-05-17 2019-10-02 ネクセル カンパニー リミテッド 組織線維化の予防又は治療用の組換えタンパク質及びこれを含む組織線維化の予防又は治療用の組成物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972337A (en) 1990-11-01 1999-10-26 Cancer Research Fund Of Contra Costa 46 kilodalton human milk fat globule (HMFG) antigen, fragments and fusion protein
IL160142A0 (en) * 2001-08-17 2004-06-20 Anosys Inc Methods and compounds for the targeting of protein to exosomes
JP4160292B2 (ja) * 2001-11-20 2008-10-01 独立行政法人科学技術振興機構 生体内のアポトーシス細胞の除去促進剤及び除去阻害剤
WO2010096713A2 (en) * 2009-02-20 2010-08-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method for the diagnosis of age-associated vascular disorders
JP2014507649A (ja) * 2011-01-18 2014-03-27 バクスター・インターナショナル・インコーポレイテッド ヒト血液中の抗βアミロイド抗体の測定
EP3021942A4 (en) * 2013-07-19 2017-04-19 The Regents of The University of California Milk fat globule epidermal growth factor 8 regulates fatty acid uptake
AU2016260190A1 (en) 2015-05-12 2017-11-23 The Regents Of The University Of California Peptide treatment for inflammation and fibrosis
KR20170013621A (ko) * 2015-07-28 2017-02-07 (주) 넥셀 Ｍｉｌｋ ｆａｔ ｇｌｏｂｕｌｅ－ＥＧＦ ｆａｃｔｏｒ（ＭＦＧ－Ｅ８）을 이용한 조직섬유화 예방 또는 치료용 조성물
CN105288592A (zh) 2015-11-02 2016-02-03 哈尔滨博翱生物医药技术开发有限公司 成纤维细胞生长因子-21成熟肽在制备肝纤维化治疗药物中的应用
GB2552473A (en) * 2016-07-21 2018-01-31 Evox Therapeutics Ltd Surface decoration of extracellular vesicles
KR102129178B1 (ko) 2018-10-25 2020-07-01 (주) 넥셀 심근경색 예방 또는 치료용 재조합 단백질을 포함하는 심근경색 예방 또는 치료용 조성물
KR102129179B1 (ko) 2018-10-25 2020-07-01 (주) 넥셀 알츠하이머병 예방 또는 치료용 재조합 단백질을 포함하는 알츠하이머병 예방 또는 치료용 조성물
KR102161892B1 (ko) 2018-10-26 2020-10-05 (주) 넥셀 특발성 폐섬유증 예방 또는 치료용 재조합 단백질을 포함하는 특발성 폐섬유증 예방 또는 치료용 조성물
JP7659499B2 (ja) 2018-10-25 2025-04-09 ネクセル カンパニー，リミテッド 線維症を治療又は予防するための組成物及び方法
MX2022002638A (es) * 2019-09-06 2022-03-25 Novartis Ag Proteinas de fusion terapeuticas.
CN118076371A (zh) 2021-04-22 2024-05-24 百进生物科技公司 用于检测和耗竭磷脂酰丝氨酸阳性细胞的磷脂酰丝氨酸结合剂
KR102758046B1 (ko) 2021-11-05 2025-01-23 (주) 넥셀 궤양성 대장염 예방 또는 치료용 재조합 단백질 및 이를 포함하는 궤양성 대장염 예방 또는 치료용 조성물

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002530348A (ja) 1998-11-24 2002-09-17 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ラクトアドヘリン又はその変異体を用いる組成物及び方法
WO2015025956A1 (ja) 2013-08-22 2015-02-26 国立大学法人九州大学 心筋障害治療用薬剤組成物、心筋障害予防用薬剤組成物、心不全治療用薬剤組成物、心不全予防用薬剤組成物、心筋障害又は心不全を治療又は予防する方法、ｍｆｇ－ｅ８、ｍｆｇ－ｅ８の使用、及び心筋障害又は心不全を治療又は予防する化合物のスクリーニング方法
JP6585296B2 (ja) 2017-05-17 2019-10-02 ネクセル カンパニー リミテッド 組織線維化の予防又は治療用の組換えタンパク質及びこれを含む組織線維化の予防又は治療用の組成物

Also Published As

Publication number Publication date
US20250115649A1 (en) 2025-04-10
WO2020084344A3 (en) 2020-07-16
JP2022509445A (ja) 2022-01-20
CN113301914A (zh) 2021-08-24
WO2020084344A2 (en) 2020-04-30
EP3870210A2 (en) 2021-09-01
US20210388041A1 (en) 2021-12-16
CN113301914B (zh) 2026-02-03
JP2024133483A (ja) 2024-10-02
EP3870210A4 (en) 2022-10-19
US12139518B2 (en) 2024-11-12

Similar Documents

Publication Publication Date Title
JP7659499B2 (ja) 線維症を治療又は予防するための組成物及び方法
JP6776380B2 (ja) 癌モデル及び関連方法
Aoki et al. Attenuation of bleomycin-induced pulmonary fibrosis by follistatin
KR101808020B1 (ko) p75NTR 뉴로트로핀 결합 단백질의 치료학적 용도
CN112168969B (zh) Ddit4l及其功能小肽对胶质母细胞瘤的抑制作用
EP1259248B1 (en) Methods for treating cancers expressing vascular endothelial growth factor d
EP2548578B1 (en) Targeting VEGF-B regulation of fatty acid transporters to modulate human diseases
US20110009337A1 (en) Q3 sparc deletion mutant and uses thereof
JP5122278B2 (ja) 眼細胞生存の促進におけるラクリチンの使用
EP1196186A2 (en) Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs
US20170218082A1 (en) Human soluble cd146, preparation and uses thereof
US20180057898A1 (en) Antifibrotic activity of gas6 inhibitor
Tomlinson et al. Tissue-targeted complement therapeutics
Su et al. Overexpression of Corin ameliorates kidney fibrosis through Inhibition of Wnt/β-Catenin signaling in mice
CN106063928A (zh) 一种多肽或其衍生物在预防和/或治疗高血压性心肌肥厚中的应用
EP1519193B1 (en) Methods for detecting cancers expressing vascular endothelial growth factor D
DE60038740T2 (de) Stimulierung oder hemmung von angiogenese und herzvaskularisierung
US20170281710A1 (en) Use of inhibitors of binding between a par-1 receptor and its ligands for the treatment of glioma
JPWO2007139120A1 (ja) アミロイドβクリアランス促進剤
JP2007528710A (ja) 内因性ペプチドおよびその活性サブフラグメント
KR20010085792A (ko) 혈관형성 및 심혈관형성의 촉진 또는 억제
Peng et al. TGF-β1/SMAD3-mediated non-canonical hedgehog signaling promotes pancreatic stellate cell activation and fibrosis in chronic pancreatitis
EP1911459A1 (en) Lymphangiogenesis promoter
JP2009523440A (ja) Ｖｅｇｆバリアント
CA2530866A1 (en) Methods and compositions for treating disorders of the extracellular matrix

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221018

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221018

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230920

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230926

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231225

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240606

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240710

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241022

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250221

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250304

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250328

R150 Certificate of patent or registration of utility model

Ref document number: 7659499

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150